ALTSTATION.IO

Medtronic plc (MDT) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$102.55

Change

-0.39%

Market Cap

$131.53B

Avg Volume

7.5M

Company Overview

Medtronic plc develops and sells a wide range of medical devices and therapies. Their offerings cater to healthcare systems, physicians, and patients globally, particularly in the U.S., Ireland, and Europe. Key products include implantable cardiac devices, surgical instruments, spinal and neurological devices, and diabetes management tools. They serve a diverse group of specialists, from cardiologists to orthopedic surgeons, ensuring that they address various medical needs through advanced technology.

As a market leader in the healthcare sector, Medtronic holds a significant competitive position against rivals like Boston Scientific and Abbott. Their extensive product portfolio and established relationships with hospitals provide them with a strong edge. However, they face threats from both competition and regulatory pressures, particularly as other companies innovate rapidly in the medical device space. Market dynamics, such as increasing demand for minimally invasive procedures, play to Medtronic’s strengths but also amplify competitive challenges.

Currently, Medtronic is pivoting to focus on core areas of growth in established divisions while streamlining operations. They have made strategic investments in robotics and advanced therapies, signaling a commitment to innovation. Recent milestones include announcing plans to expand their diabetes portfolio, which reflects an intent to tap into the growing demand for diabetes management solutions. Overall, while facing headwinds in certain segments, Medtronic is strategically positioning itself for sustained growth.

Key Financials

Market Cap

$131.53B

Revenue

$34.76B

EBITDA

$9.57B

Gross Margin

65.6%

Profit Margin

13.7%

Revenue Growth

6.6%

Total Cash

$8.33B

Total Debt

$29.10B

Free Cash Flow

$3.95B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

27.79

Forward P/E

16.75

Beta

0.72

52-Week High

$106.33

52-Week Low

$79.55

EPS

$3.69

50-Day Avg

$99.92

200-Day Avg

$92.88

Price/Book

2.70

Technical Analysis

The overall trend for Medtronic plc (MDT) over the past 52 weeks has been upward, characterized by a consistent increase from approximately $85 in early March to a current price of $102.55. The stock has shown strength, with a 16% increase over the period, and has effectively utilized a rising support line. Key support levels are observed around $90, which has held multiple times throughout the year, while resistance is evident near $102.9, the recent high reached in January. The chart displays a series of higher lows and higher highs, indicating bullish momentum and a gradual accumulation of gains. In the past few weeks, MDT has demonstrated renewed upward momentum, particularly with price action holding above the 50-day moving average (blue line) and pushing towards resistance. Currently, the price sits relatively near the upper end of its 52-week range, suggesting strong buying interest and potential for a breakout above the $102.9 level.

Recent News and Developments

Market Update

Here’s a summary of the latest news and developments for Medtronic plc (MDT) stock in the past week:

1. Medtronic Announces Intent to Acquire CathWorks for up to $585 Million

Medtronic announced on February 3, 2026, its intention to acquire CathWorks, a privately held medical device company. This acquisition, valued at up to $585 million, aims to bolster Medtronic’s interventional cardiology portfolio by integrating CathWorks’ FFRangio® System, an AI-driven platform for diagnosing coronary artery disease. The deal, which follows a 2022 strategic partnership, is subject to U.S. FTC clearance and is expected to be immaterial to fiscal year 2027 EPS and neutral to accretive thereafter.

2. Citigroup Resumes Coverage on Medtronic with a “Buy” Rating

On February 3, 2026, Citigroup resumed its coverage of Medtronic plc with a “Buy” rating and set a price target of $117. This positive analyst outlook contributes to a “Moderate Buy” consensus rating among analysts, with a mean price target of $110.50 suggesting a potential upside from current levels.

Market Sentiment and Analyst Recommendations

Bull Case

Medtronic is firing on multiple cylinders right now. Revenue growth of 6.6% is solid for a $35B company, and the pipeline is stacked with near-term catalysts. The CathWorks acquisition for $585 million bolsters interventional cardiology with an AI-driven diagnostic platform that addresses a real market gap. Diabetes is expanding fast too — the new Medicare approvals and FDA clearances for the MiniMed 780G system open access to a broader patient population, including type 2 diabetics who were previously underserved. Analyst consensus is strong at 23 buys with a $110.88 target, implying 8% upside from current levels. The stock has momentum on its side, up 16% over 52 weeks with a clear uptrend and support holding at $90. At 27.79x P/E, you’re paying for growth but not an unreasonable premium for a diversified medtech leader with recurring revenue streams.

Bear Case

The debt load is the real problem here. Medtronic carries $29.10 billion in debt against $8.33 billion in cash, leaving a net debt position of $20.77 billion. That’s 6.3x net debt to operating cash flow territory, which constrains financial flexibility and increases refinancing risk in a higher rate environment. The P/E of 27.79 is elevated for a company growing revenue at just 6.6% — you’re betting on margin expansion or multiple expansion, neither guaranteed. The CathWorks deal being “immaterial to fiscal 2027 EPS” tells you it won’t move the needle near-term, and integration risk is real. Competition in medtech is relentless, and Medtronic’s core businesses face pressure from smaller, more agile competitors. The stock is already near the top of its 52-week range at $102.55, leaving limited room for error if earnings disappoint or macro conditions tighten.

What to Watch

Monitor the FTC clearance timeline for CathWorks — any regulatory delays or conditions could signal broader antitrust scrutiny of Medtronic’s M&A strategy. Track quarterly revenue growth rates, specifically in the Diabetes and Interventional Cardiology segments, to see if the new FDA clearances and Medicare approvals translate to actual patient adoption and revenue acceleration. Watch gross margin trends in earnings reports; Medtronic needs to prove it can expand margins organically rather than rely on acquisition synergies. The debt-to-EBITDA ratio should be a focus point — management needs to demonstrate deleveraging progress or the stock could face multiple compression if rates stay elevated. Key price level to watch is $102.90 resistance; a break above that with volume suggests momentum to the $110+ target. If quarterly guidance comes in below consensus, the stock could quickly test the $95-97 support zone. Medtronic reports earnings quarterly, so the next catalyst window is typically 4-6 weeks out depending on fiscal quarter timing.

Analyst Consensus

BUY

Based on 23 analyst opinions

Low Target

$97.20

Mean Target

$110.88

High Target

$121.00

Earnings and Financial Data

Sector

Healthcare

Industry

Medical Devices

Employees

95,000

Earnings & Dividends

Next Earnings

Feb 17, 2026

EPS (Trailing)

$3.69

Dividend Yield

276.0%

Payout Ratio

76.4%

Frequently Asked Questions

Is MDT a good stock to buy?

Analysts recommend MDT as a BUY, setting a target price at $110.88, which suggests potential upside from its current price of $102.55. Given its position in the healthcare sector and solid fundamentals, it shows promise for growth.

What is MDT’s price target?

The average price target for MDT is $110.88, which indicates an upside of about 8% from its current trading level. This target reflects analyst confidence in the company’s growth trajectory.

Does MDT pay a dividend?

Yes, Medtronic offers a dividend yield of 276.0%, which is significantly high. This makes MDT appealing for income-focused investors, particularly in the medical devices sector.

What is MDT’s P/E ratio?

MDT’s current P/E ratio is 27.79, with a forward P/E of 16.75. These figures suggest that while the stock is currently valued at a premium, there may be better earnings growth expected in the future.

What is MDT’s market cap?

Medtronic has a market cap of $131.53 billion. This substantial market value reflects its strong standing in the medical devices industry and a robust business model.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.